Back to Search Start Over

ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants

ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants

Authors :
Jeffrey Seow
Carl Graham
Sadie R. Hallett
Thomas Lechmere
Thomas J.A. Maguire
Isabella Huettner
Daniel Cox
Hataf Khan
Suzanne Pickering
Rebekah Roberts
Anele Waters
Christopher C. Ward
Christine Mant
Michael J. Pitcher
Jo Spencer
Julie Fox
Michael H. Malim
Katie J. Doores
Source :
Cell reports. 39(5)
Publication Year :
2021

Abstract

Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response.

Details

ISSN :
22111247
Volume :
39
Issue :
5
Database :
OpenAIRE
Journal :
Cell reports
Accession number :
edsair.doi.dedup.....11998d6463c0ba8fa9ebd76e43431f78